CircSPARC promotes esophageal squamous cell carcinoma through an HNRNPC-EPN2 splicing axis that activates Wnt/β-Catenin signaling.
Saved in:
| Title: | CircSPARC promotes esophageal squamous cell carcinoma through an HNRNPC-EPN2 splicing axis that activates Wnt/β-Catenin signaling. |
|---|---|
| Authors: | Dai S; Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.; Key Laboratory of Tumor Prevention and Precision Diagnosis and Treatment of Hebei, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China., Zhang C; Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.; Key Laboratory of Tumor Prevention and Precision Diagnosis and Treatment of Hebei, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China., Wei Z; Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.; Key Laboratory of Tumor Prevention and Precision Diagnosis and Treatment of Hebei, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China., Liu Y; Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.; Key Laboratory of Tumor Prevention and Precision Diagnosis and Treatment of Hebei, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China., Wen Y; Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.; Department of Chemoradiotherapy, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei, 063000, China., Chen J; Department of Blood Transfusion, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China., Li X; Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.; Key Laboratory of Tumor Prevention and Precision Diagnosis and Treatment of Hebei, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China., Wei S; Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China.; Key Laboratory of Tumor Prevention and Precision Diagnosis and Treatment of Hebei, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China., Sun G; Department of Chemoradiotherapy, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei, 063000, China. sunguogui@ncst.edu.cn., Zhao L; Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China. lianmei555@hebmu.edu.cn.; Key Laboratory of Tumor Prevention and Precision Diagnosis and Treatment of Hebei, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, China. lianmei555@hebmu.edu.cn. |
| Source: | Molecular cancer [Mol Cancer] 2026 May 28; Vol. 25 (1). Date of Electronic Publication: 2026 May 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
